These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 25668198

  • 1. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
    Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Van Alfen AA, Van Leeuwen M, Van Wieringen H, Wegdam-den Boer ME, Zwaveling-Soonawala N, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
    [Abstract] [Full Text] [Related]

  • 2. Bone mineral density during 3 years of growth hormone in previously GH-treated young adults with PWS.
    Damen L, Grootjen LN, Donze SH, de Graaff LCG, van der Velden JAEM, Hokken-Koelega ACS.
    Eur J Endocrinol; 2021 May 04; 184(6):773-782. PubMed ID: 33769952
    [Abstract] [Full Text] [Related]

  • 3. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.
    de Lind van Wijngaarden RF, Festen DA, Otten BJ, van Mil EG, Rotteveel J, Odink RJ, van Leeuwen M, Haring DA, Bocca G, Mieke Houdijk EC, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2009 Oct 04; 94(10):3763-71. PubMed ID: 19622627
    [Abstract] [Full Text] [Related]

  • 4. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
    Donze SH, Kuppens RJ, Bakker NE, van Alfen-van der Velden JAEM, Hokken-Koelega ACS.
    Clin Endocrinol (Oxf); 2018 Jun 04; 88(6):806-812. PubMed ID: 29418016
    [Abstract] [Full Text] [Related]

  • 5. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
    Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Schroor EJ, Van Alfen AA, Van Leeuwen M, Van Pinxteren-Nagler E, Van Wieringen H, Vreuls RC, Zwaveling-Soonawala N, de Ridder MA, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2013 Oct 04; 98(10):4013-22. PubMed ID: 24001750
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF, Siemensma EP, Festen DA, Otten BJ, van Mil EG, Rotteveel J, Odink RJ, Bindels-de Heus GC, van Leeuwen M, Haring DA, Bocca G, Houdijk EC, Hoorweg-Nijman JJ, Vreuls RC, Jira PE, van Trotsenburg AS, Bakker B, Schroor EJ, Pilon JW, Wit JM, Drop SL, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2009 Nov 04; 94(11):4205-15. PubMed ID: 19837938
    [Abstract] [Full Text] [Related]

  • 7. Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD.
    Jørgensen AP, Ueland T, Sode-Carlsen R, Schreiner T, Rabben KF, Farholt S, Høybye C, Christiansen JS, Bollerslev J.
    J Clin Endocrinol Metab; 2013 Apr 04; 98(4):E753-60. PubMed ID: 23436915
    [Abstract] [Full Text] [Related]

  • 8. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2008 Sep 04; 69(3):443-51. PubMed ID: 18363884
    [Abstract] [Full Text] [Related]

  • 9. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
    Bakker NE, Siemensma EP, Koopman C, Hokken-Koelega AC.
    Horm Res Paediatr; 2015 Sep 04; 83(5):321-31. PubMed ID: 25764996
    [Abstract] [Full Text] [Related]

  • 10. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment.
    Lem AJ, van der Kaay DC, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2013 Jan 04; 98(1):77-86. PubMed ID: 23125290
    [Abstract] [Full Text] [Related]

  • 11. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
    Myers SE, Carrel AL, Whitman BY, Allen DB.
    J Pediatr; 2000 Jul 04; 137(1):42-9. PubMed ID: 10891820
    [Abstract] [Full Text] [Related]

  • 12. Effects of 8 years of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
    Grootjen LN, Rutges JPHJ, Damen L, Donze SH, Juriaans AF, Kerkhof GF, Hokken-Koelega ACS.
    Eur J Endocrinol; 2021 May 21; 185(1):47-55. PubMed ID: 33886496
    [Abstract] [Full Text] [Related]

  • 13. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
    Carrel AL, Myers SE, Whitman BY, Allen DB.
    J Clin Endocrinol Metab; 2002 Apr 21; 87(4):1581-5. PubMed ID: 11932286
    [Abstract] [Full Text] [Related]

  • 14. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF, de Klerk LW, Festen DA, Duivenvoorden HJ, Otten BJ, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2009 Apr 21; 94(4):1274-80. PubMed ID: 19158197
    [Abstract] [Full Text] [Related]

  • 15. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY, Myers S, Carrel A, Allen D.
    Pediatrics; 2002 Feb 21; 109(2):E35. PubMed ID: 11826245
    [Abstract] [Full Text] [Related]

  • 16. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E, Hughes I, Harris M, Ambler G, Crock P, Verge CF, Craig ME, Bergman P, Werther G, van Driel M, Davies PS, Choong CS.
    J Paediatr Child Health; 2013 Dec 21; 49(12):1045-51. PubMed ID: 23781979
    [Abstract] [Full Text] [Related]

  • 17. Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy.
    Festen DA, van Toorenenbergen A, Duivenvoorden HJ, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2007 Apr 21; 92(4):1549-54. PubMed ID: 17264186
    [Abstract] [Full Text] [Related]

  • 18. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.
    Högler W, Briody J, Moore B, Lu PW, Cowell CT.
    Bone; 2005 Nov 21; 37(5):642-50. PubMed ID: 16139578
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
    Mogul HR, Lee PD, Whitman BY, Zipf WB, Frey M, Myers S, Cahan M, Pinyerd B, Southren AL.
    J Clin Endocrinol Metab; 2008 Apr 21; 93(4):1238-45. PubMed ID: 18211968
    [Abstract] [Full Text] [Related]

  • 20. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
    Bakker NE, Lindberg A, Heissler J, Wollmann HA, Camacho-Hübner C, Hokken-Koelega AC, KIGS Steering Committee.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1702-1711. PubMed ID: 28323917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.